PerkinElmer Inc. has completed its acquisition of Hopkinton-based Caliper Life Sciences at a purchase price of about $600 million, or $10.50 per share of Caliper stock.
The deal involving the laboratory service companies was announced in September. Robert F. Friel, chairman and CEO of Waltham-based PerkinElmer, said Caliper CEO Kevin Hrusovsky will remain with Perkin Elmer as head of a newly combined $500 million-a-year business that will integrate the Caliper organization with PerkinElmer’s research business. “Kevin’s deep industry expertise and successful track record in leading Caliper will provide PerkinElmer with an even stronger foundation,” Friel said in a statement.
Hrusovsky added: “We are very excited about the opportunities ahead of us … Our shared vision for giving customers the tools and insights they need to understand the origins of disease, create new therapies, and transform personalized medicine is a compelling road map for success as we move forward together.”
Â
Read more
